One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
about
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsHuman β-cell regeneration: progress, hurdles, and controversy.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaIns1(Cre) knock-in mice for beta cell-specific gene recombination.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats.Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?An updated review on cancer risk associated with incretin mimetics and enhancers.GLP-1 based therapies: clinical implications for gastroenterologists.Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in VitroThe glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Pancreatic Safety of Sitagliptin in the TECOS Study.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice
P2860
Q27021870-C6EA8341-443D-4B32-A53A-488BBD0B19B3Q33776142-75A6EC35-8465-4ECB-A47E-B696AF68219CQ34041974-E2974AE5-84A6-42A1-A7DE-F0625FC735BAQ35059488-FFA59973-5529-4AEE-8E6F-332C6CE3BF90Q37193295-5806DA99-1C76-4D83-8E22-EBE9232444A3Q37660923-65C4632C-4B2D-4A8B-A8DA-BBFF405C1CDBQ37730690-E77A2DEE-C449-4B0E-BBC8-CA514E960CEEQ38205588-610A3152-5890-4A3C-B297-BE173E9F5ED7Q38255715-78EE5A2F-35D5-47F5-94BF-D349EA15C6EBQ38388920-43FEC842-24B3-446B-A00F-48E06195BAE8Q38703292-8F127B08-E112-4649-98B8-3AB618353833Q38758608-C1544454-59F9-4CBF-8794-EF5108EBBCB3Q45778975-E3C1665D-2B0D-4527-8A73-E61C17839BCAQ47386188-2A7C145B-FB9C-42D4-92CF-7AF7FD11FD25Q50219805-24EA5228-FE3A-4321-803E-CA2FCEBFCD18Q52780711-9C026EC1-D828-4CC3-83DE-B56580025F27Q57137026-21F21154-C10F-409D-A25A-54DABFA31446
P2860
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@en
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@nl
type
label
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@en
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@nl
prefLabel
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@en
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@nl
P2093
P2860
P1476
One year of sitagliptin treatm ...... pancreatic neoplasia in mice.
@en
P2093
Daniel T Meier
Lynn C Goldstein
Rebecca L Hull
Sakeneh Zraika
Shoba L Subramanian
Thanya Samarasekera
P2860
P304
P356
10.1152/AJPENDO.00025.2013
P577
2013-06-04T00:00:00Z